Details of the Drug Combination

General Information of Drug Combination (ID: DCKTBEW)

Drug Combination Name
Nitrofurantoin Ampicillin
Indication
Disease Entry Status REF
Nephrolithiasis Phase 1 [1]
Component Drugs Nitrofurantoin   DM7PQIK Ampicillin   DMHWE7P
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nitrofurantoin
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [2]
Nitrofurantoin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Deoxyribonucleic acid (Bact DNA) TTS1W4A NOUNIPROTAC Breaker [5]
------------------------------------------------------------------------------------
Nitrofurantoin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Nitrofurantoin Interacts with 10 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Metabolism [7]
Nitroreductase (NTR) DEAVXGM A0A412R9E4_9FIRM Metabolism [8]
NADPH-dependent oxidoreductase (nfrA) DE82GV7 NRFA_STAA8 Metabolism [9]
NADPH-dependent nitroreductase (nfrA1) DE21PLI NFRA1_BACSU Metabolism [10]
Nitroreductase (NTR) DE7XBKW A0A174SJF2_9CLOT Metabolism [8]
Nitroreductase (NTR) DEP7ECA B1R7B9_CLOPF Metabolism [8]
Nitroreductase (NTR) DEH3ABM A0A351QTB1_CLOSP Metabolism [8]
Nitroreductase (NTR) DE3U2Y6 A0A377KR04_ENTCA Metabolism [11]
Nitroreductase (NTR) DEUW4J0 A0A376H6M5_ENTGA Metabolism [11]
Nitroreductase (NTR) DE5LYXF A0A2X3BKF5_CLOSG Metabolism [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DME(s)
Nitrofurantoin Interacts with 7 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Transport [13]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [14]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [15]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Decreases Activity [16]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Increases Expression [17]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [18]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Response To Substance [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DOT(s)
Indication(s) of Ampicillin
Disease Entry ICD 11 Status REF
Acute epiglottitis N.A. Approved [3]
Acute gonococcal cervicitis N.A. Approved [3]
Acute otitis media AB00 Approved [3]
Bacillary dysentery 1A02 Approved [3]
Bacteremia 1A73 Approved [3]
Bacterial endocarditis N.A. Approved [3]
Bacterial infection 1A00-1C4Z Approved [4]
Cholangitis N.A. Approved [3]
Chorioamnionitis N.A. Approved [3]
Dysentery N.A. Approved [3]
Escherichia coli meningitis N.A. Approved [3]
Meningococcal meningitis N.A. Approved [3]
Peritonitis N.A. Approved [3]
Pneumococcal meningitis N.A. Approved [3]
Staphylococcal pneumonia N.A. Approved [3]
Staphylococcus aureus infection N.A. Approved [3]
Streptococcal pneumonia N.A. Approved [3]
Urinary tract infection GC08 Approved [3]
Paratyphoid fever N.A. Investigative [3]
Pelvic inflammatory disease GA05 Investigative [3]
Sinusitis CA0A.Z Investigative [3]
Ampicillin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Binder [21]
------------------------------------------------------------------------------------
Ampicillin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [22]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [23]
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [24]
------------------------------------------------------------------------------------
Ampicillin Interacts with 13 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
N-acylhomoserine lactone acylase (lacA) DEIU0XN A0A0A1VBK6_9BURK Metabolism [25]
Beta-lactamase (blaB) DET9I1W BLAC_BACUN Metabolism [26]
AmpC beta-lactamase (ampC) DERI7LO A0A0H3KQ39_BURM1 Metabolism [27]
Beta-lactamase (blaB) DE3FVRW BLA2_BAC17 Metabolism [28]
Beta-lactamase (blaB) DETDS7E A0A2S0LB67_9FLAO Metabolism [28]
Beta-lactamase (blaB) DEQX0DG Q8RIK5_FUSNN Metabolism [28]
Beta-lactamase (blaB) DEC7JEF A0A1S1G219_9NEIS Metabolism [28]
Beta-lactamase (blaB) DEXB2A9 A0A379CPC3_PLESH Metabolism [29]
Beta-lactamase (blaB) DEBKS91 A0A1B1FBM9_ACIBA Metabolism [30]
Beta-lactamase (blaB) DEWMGC3 A0A2U9SV73_9BURK Metabolism [28]
Beta-lactamase (blaB) DEWYT5M D4HFC4_CUTAS Metabolism [28]
Beta-lactamase (blaB) DE52KD0 Q6EZ46_RALPI Metabolism [28]
Beta-lactamase (blaB) DEG5Y4W A0A344X3A2_STASP Metabolism [28]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DME(s)
Ampicillin Interacts with 77 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Decreases Activity [31]
Phospholemman (FXYD1) OTNKT6GP PLM_HUMAN Increases Expression [20]
Interferon-related developmental regulator 1 (IFRD1) OT4SQMLQ IFRD1_HUMAN Decreases Expression [20]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Expression [20]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Decreases Expression [20]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Decreases Expression [20]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Decreases Expression [20]
Dickkopf-related protein 1 (DKK1) OTRDLUSP DKK1_HUMAN Increases Expression [20]
Chloride intracellular channel protein 3 (CLIC3) OT5KUZ3A CLIC3_HUMAN Increases Expression [20]
Ceruloplasmin (CP) OTM8JE4Y CERU_HUMAN Increases Expression [20]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Decreases Expression [20]
Cystatin-A (CSTA) OT1K68KE CYTA_HUMAN Decreases Expression [20]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [20]
Arginase-1 (ARG1) OTHZITAM ARGI1_HUMAN Increases Expression [20]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Increases Expression [20]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [20]
Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3) OT2HZK5M GTR3_HUMAN Increases Expression [20]
Creatine kinase B-type (CKB) OTUCKOTT KCRB_HUMAN Increases Expression [20]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Increases Expression [20]
Transcription factor JunD (JUND) OTNKACJD JUND_HUMAN Increases Expression [20]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Increases Expression [20]
Gastricsin (PGC) OTQRITKI PEPC_HUMAN Increases Expression [20]
Parathymosin (PTMS) OT9PS4Q0 PTMS_HUMAN Increases Expression [20]
Calreticulin (CALR) OTYD2TR1 CALR_HUMAN Increases Expression [20]
Protein-lysine 6-oxidase (LOX) OT1C2HIU LYOX_HUMAN Increases Expression [20]
Dual specificity protein phosphatase 1 (DUSP1) OTN6BR75 DUS1_HUMAN Increases Expression [20]
Sodium- and chloride-dependent creatine transporter 1 (SLC6A8) OT88C8JA SC6A8_HUMAN Increases Expression [20]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Decreases Expression [20]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Decreases Expression [20]
Rho GDP-dissociation inhibitor 1 (ARHGDIA) OTEXWJDO GDIR1_HUMAN Increases Expression [20]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Decreases Expression [20]
Myc-associated zinc finger protein (MAZ) OTEHKN1M MAZ_HUMAN Increases Expression [20]
Tropomyosin alpha-4 chain (TPM4) OTN4YLYR TPM4_HUMAN Increases Expression [20]
Transgelin (TAGLN) OTAEZ0KP TAGL_HUMAN Increases Expression [20]
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Decreases Expression [20]
Prostaglandin reductase 1 (PTGR1) OTMAR351 PTGR1_HUMAN Decreases Expression [20]
Ankyrin repeat domain-containing protein 1 (ANKRD1) OTHJ7JV9 ANKR1_HUMAN Increases Expression [20]
Na(+)/H(+) exchange regulatory cofactor NHE-RF2 (NHERF2) OTRHB9SR NHRF2_HUMAN Increases Expression [20]
Carbonic anhydrase 9 (CA9) OTNA51XT CAH9_HUMAN Increases Expression [20]
Dual specificity protein phosphatase 7 (DUSP7) OT6Z5AHP DUS7_HUMAN Increases Expression [20]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) OT25JBA3 F263_HUMAN Increases Expression [20]
Filamin A-interacting protein 1-like (FILIP1L) OTPY8IMS FIL1L_HUMAN Increases Expression [20]
Angiomotin (AMOT) OTWHDG9B AMOT_HUMAN Increases Expression [20]
Glycerol-3-phosphate acyltransferase 3 (GPAT3) OTJUGPK0 GPAT3_HUMAN Decreases Expression [20]
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3) OTDMU3GP CR3L3_HUMAN Decreases Expression [20]
Leukocyte-associated immunoglobulin-like receptor 2 (LAIR2) OTKCADXC LAIR2_HUMAN Decreases Expression [20]
Sterile alpha motif domain-containing protein 1 (SAMD1) OT2LK4JW SAMD1_HUMAN Increases Expression [20]
Lipocalin-15 (LCN15) OT9YXMIL LCN15_HUMAN Increases Expression [20]
Protein MTSS 2 (MTSS2) OTKMNSBF MTSS2_HUMAN Increases Expression [20]
Carbohydrate sulfotransferase 15 (CHST15) OTNTM2SP CHSTF_HUMAN Increases Expression [20]
Solute carrier family 22 member 15 (SLC22A15) OT60WAAI S22AF_HUMAN Decreases Expression [20]
BPI fold-containing family B member 2 (BPIFB2) OTXWTWQ9 BPIB2_HUMAN Increases Expression [20]
Arrestin domain-containing protein 4 (ARRDC4) OTINJ0FX ARRD4_HUMAN Decreases Expression [20]
Phospholipid phosphatase-related protein type 1 (PLPPR1) OT4A560N PLPR1_HUMAN Increases Expression [20]
Jun dimerization protein 2 (JDP2) OTW35WKX JDP2_HUMAN Decreases Expression [20]
Aquaporin-3 (AQP3) OT2J7JPD AQP3_HUMAN Decreases Expression [20]
Arrestin domain-containing protein 3 (ARRDC3) OTAKW7R9 ARRD3_HUMAN Decreases Expression [20]
Small integral membrane protein 14 (SMIM14) OT47IF19 SIM14_HUMAN Decreases Expression [20]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Decreases Expression [20]
Homeobox protein Hox-D1 (HOXD1) OTN4V9ZF HXD1_HUMAN Increases Expression [20]
Regulator of cell cycle RGCC (RGCC) OTYJMLWM RGCC_HUMAN Increases Expression [20]
Serine/threonine-protein kinase Sgk2 (SGK2) OTCTVSHF SGK2_HUMAN Decreases Expression [20]
Endothelial cell-specific molecule 1 (ESM1) OT331Y8V ESM1_HUMAN Decreases Expression [20]
]-phosphatase 2, mitochondrial (PDP2) OTADNMGK PDP2_HUMAN Increases Expression [20]
Cell cycle progression protein 1 (CCPG1) OT0IHDKL CCPG1_HUMAN Decreases Expression [20]
Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) (SLC6A14) OTN51IPT S6A14_HUMAN Increases Expression [20]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [20]
Proliferation-associated protein 2G4 (PA2G4) OT7IG7HT PA2G4_HUMAN Increases Expression [20]
Pirin (PIR) OT8ALXHU PIR_HUMAN Increases Expression [32]
Tripartite motif-containing protein 16 (TRIM16) OTLRXYOZ TRI16_HUMAN Increases Expression [32]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [32]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases Expression [32]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [33]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [33]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Increases Expression [33]
Excitatory amino acid transporter 2 (SLC1A2) OTEP3QGN EAA2_HUMAN Increases Expression [34]
ATP-binding cassette sub-family C member 4 (ABCC4) OTO27PAL MRP4_HUMAN Increases Transport [35]
------------------------------------------------------------------------------------
⏷ Show the Full List of 77 DOT(s)

References

1 ClinicalTrials.gov (NCT02829060) Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009175.
3 Ampicillin FDA Label
4 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061936.
5 On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14.
6 The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005 May;67(5):1758-64.
7 Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
8 Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
9 Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev. 2008 May;32(3):474-500.
10 Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.
11 Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
12 Biotransformation of 1-nitropyrene in intestinal anaerobic bacteria. Microbiol Immunol. 1982;26(11):993-1005.
13 Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos. 2007 Feb;35(2):268-74.
14 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
15 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
16 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
17 Stimulation of de novo glutathione synthesis by nitrofurantoin for enhanced resilience of hepatocytes. Cell Biol Toxicol. 2022 Oct;38(5):847-864. doi: 10.1007/s10565-021-09610-3. Epub 2021 May 22.
18 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
19 Roles of DT diaphorase in the genotoxicity of nitroaromatic compounds in human and fish cell lines. J Toxicol Environ Health. 1997 Oct 10;52(2):137-48. doi: 10.1080/00984109708984057.
20 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
21 Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
22 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
23 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
24 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
25 A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
26 Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
27 Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
28 Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
29 Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80.
30 Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
31 Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol Pharm Bull. 2006 Aug;29(8):1559-63.
32 Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):283-92.
33 Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
34 Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem. 2007 Jan 19;282(3):1727-37. doi: 10.1074/jbc.M609822200. Epub 2006 Nov 30.
35 Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.